Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291232 · ClinicalTrials.gov registry record · Phase 1
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
A Phase 1 study of Obesity, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT07291232 is a Phase 1 study of Obesity that is actively recruiting participants, run by AbbVie. The registered enrollment target is 96 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07291232, a Phase 1 study of Obesity, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABBV-295
Study Locations (1)
Illinois
- Acpru /Id# 278624 - Grayslake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07291232
The ClinicalTrials.gov registry entry for NCT07291232 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07291232 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07291232 about?
NCT07291232 is a clinical study titled "A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity". This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
What is the current status of trial NCT07291232?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2025-11-19. Estimated completion is 2026-10.
What conditions does trial NCT07291232 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07291232?
The interventions under investigation include: Placebo (DRUG), ABBV-295 (DRUG).
Who is sponsoring clinical trial NCT07291232?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291232 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.